Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

873 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice.
Kai Y, Hikita H, Tatsumi T, Nakabori T, Saito Y, Morishita N, Tanaka S, Nawa T, Oze T, Sakamori R, Yakushijin T, Hiramatsu N, Suemizu H, Takehara T. Kai Y, et al. J Gastroenterol. 2015 Nov;50(11):1145-51. doi: 10.1007/s00535-015-1108-6. Epub 2015 Jul 25. J Gastroenterol. 2015. PMID: 26208695
DNase II activated by the mitochondrial apoptotic pathway regulates RIP1-dependent non-apoptotic hepatocyte death via the TLR9/IFN-β signaling pathway.
Saito Y, Hikita H, Nozaki Y, Kai Y, Makino Y, Nakabori T, Tanaka S, Yamada R, Shigekawa M, Kodama T, Sakamori R, Tatsumi T, Takehara T. Saito Y, et al. Among authors: kai y. Cell Death Differ. 2019 Mar;26(3):470-486. doi: 10.1038/s41418-018-0131-6. Epub 2018 May 31. Cell Death Differ. 2019. PMID: 29855540 Free PMC article.
Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
Doi A, Hikita H, Kai Y, Tahata Y, Saito Y, Nakabori T, Yamada R, Kodama T, Sakamori R, Murayama A, Nitta S, Asahina Y, Suemizu H, Tatsumi T, Kato T, Takehara T. Doi A, et al. Among authors: kai y. J Gastroenterol. 2019 May;54(5):449-458. doi: 10.1007/s00535-018-01541-x. Epub 2019 Jan 25. J Gastroenterol. 2019. PMID: 30684016
Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S-1 as second-line chemotherapy in metastatic pancreatic cancer.
Ikezawa K, Kiyota R, Takada R, Daiku K, Maeda S, Imai T, Abe Y, Kai Y, Yamai T, Fukutake N, Nakabori T, Ashida R, Uehara H, Tabuchi T, Katayama K, Ohkawa K. Ikezawa K, et al. Among authors: kai y. JGH Open. 2021 May 10;5(6):679-685. doi: 10.1002/jgh3.12555. eCollection 2021 Jun. JGH Open. 2021. PMID: 34124386 Free PMC article.
The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer.
Takada R, Ikezawa K, Daiku K, Maeda S, Abe Y, Urabe M, Kai Y, Yamai T, Fukutake N, Nakabori T, Uehara H, Ashida R, Akita H, Takahashi H, Teshima T, Ohkawa K. Takada R, et al. Among authors: kai y. Cancers (Basel). 2021 Sep 21;13(18):4733. doi: 10.3390/cancers13184733. Cancers (Basel). 2021. PMID: 34572960 Free PMC article.
873 results